ERBB2 and breast carcinoma: However, no consensus was reached on the need for BCMS to give accurate prognosis for patients with ER + advanced and/or metastatic breast cancer (S59), HER2 + advanced breast cancer (S63), or triple-negative advanced breast cancer (S67).